Giuffre Randall Michael 4

What Happened
Randall Michael Giuffre, a director of DiaMedica Therapeutics Inc. (DMAC), was granted 40,412 shares in an award/derivative transaction on 2026-06-01. The shares were issued at $0.00 (no cash paid), so the immediate cash value reported is $0. This is an equity award (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-01; filing date: 2026-06-03 (Form 4 accession 0001759822-26-000004). No late filing indicated in the report.
• Shares/amount: 40,412 shares granted at $0.00 per share (total reported value $0).
• Shares owned after transaction: Not specified in the filing.
• Footnote: F1 — the award is scheduled to vest in four equal quarterly installments.
• Transaction type: Award/grant (derivative); code A.

Context
This grant appears to be a typical equity compensation award subject to vesting, rather than an immediate purchase or sale. Such awards are common for directors as part of compensation and only convert to fully vested ownership over time per the stated schedule.